Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study-Reference-Cited by-同舟云学术

Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study

Published:2022-02 Issue:2 Volume:40 Page:64.e1-64.e8
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Sasaki Daichi,Hatakeyama Shingo^ORCID,Kawaguchi Hideo,Hatayama Yoshiomi^ORCID,Ishibashi Yusuke,Kusaka Ayumu,Noro Daisuke^ORCID,Tanaka Toshikazu,Ito Hiroyuki^ORCID,Okuyama Yoshiharu,Okamoto Teppei,Yamamoto Hayato,Yoneyama Takahiro,Hashimoto Yasuhiro,Aoki Masahiko^ORCID,Ohyama Chikara

Funder

JSPS

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference30 articles.

1. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part ii-2020 update: treatment of relapsing and metastatic prostate cancer;Cornford;Eur Urol,2021

2. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients;Shiota;Cancer Sci,2021

3. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: a subgroup analysis of the phase III ARCHES study;Iguchi;Int J Urol,2021

4. Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study;Uemura;Int J Urol,2021

5. Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database;Chikamatsu;Int J Urol,2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive and Prognostic 18F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with 223Ra;Cancers;2024-07-29

2. Real‐world safety and effectiveness of radium‐223 in patients with metastatic castration‐resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study;International Journal of Cancer;2024-06-26

3. Metastatic castration resistant prostate cancer patients’ experience with Radium-223 treatment in Japan;Future Oncology;2024-01-26

4. Bone‐modifying agents are protective for symptomatic skeletal events in Radium‐223 treatment;International Journal of Urology;2023-07-27

5. Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer;Medicine International;2023-07-11